Advanced search
Publication Cover
Pharmacogenomics Volume 10, 2009 - Issue 3
Submit an article Journal homepage
175
Views
0
CrossRef citations to date
0
Altmetric
Review

Cutaneous Leishmaniasis: Disease Susceptibility and Pharmacogenetic Implications

Mahreen AmeenSt John‘s Institute of Dermatology, St Thomas‘Hospital, Lambeth Palace Road, LondonSE1 7EH, UK.Tel.: +44 207 188 6412; Fax: +44 207 188 6421;[email protected]
Pages 451-461 | Published online: 16 Mar 2009

Bibliography

  • Desjeux P : Leishmaniasis: current situation and new perspectives.Comp. Immunol. Microbiol. Infect. Dis.27 , 305–318 (2004).
  • Desjeux P : The increase in risk factors for leishmaniasis worldwide.Trans. R. Soc. Trop. Med. Hyg.95(3) , 239–243 (2001).
  • Reyburn H , RowlandM, MohsenM, KhanB, DaviesC: The prolonged epidemic of anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: ‘bringing down the neighbourhood‘.Trans. R. Soc. Trop. Med. Hyg.97(2) , 170–176 (2003).
  • Lawn SD , WhethamJ, ChiodiniPL et al.: New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers.QJM97(12) , 781–788 (2004).
  • Weina PJ , NeafieRC, WortmannG et al.: Old world leishmaniasis: an emerging infection among deployed US military and civilian workers.Clin. Infect. Dis.39(11) , 1674–1680 (2004).
  • Maroli M , RossiL, BaldelliR et al.:The northward spread of leishmaniasis in Italy: evidence from retrospective and ongoing studies on the canine reservoir and phlebotomine vectors. Trop. Med. Int. Health13(2) , 256–264 (2008).
  • Dujardin JC , CampinoL, CañavateC et al.: Spread of vector-borne diseases and neglect of leishmaniasis, Europe.Emerging Infect. Dis.14(7) , 1013–1018 (2008).
  • Karunaweera ND , PratlongF, SiriwardaneHV, IhalamullaRL, DedetJP: Leishmania donovani MON-37 is the causative agent of cutaneous leishmaniasis in Sri Lanka.Trans. R. Soc. Trop. Med. Hyg.97 , 380–381 (2003).
  • Sharma NL , MahajanVK, KangaA et al.: Localized cutaneous leishmaniasis due to Leishmania donovani and Leishmania tropica: preliminary findings of the study of 161 new cases from a new endemic focus in Himachal Pradesh, India.Am. J. Trop. Med. Hyg.72 , 819–824 (2005).
  • Herwaldt BL : Leishmaniasis.Lancet354 , 1191–1199 (1999).
  • Reed SG , ScottP: T-cell and cytokine responses in leishmaniasis.Curr. Opin. Immunol.5 , 524–531 (1993).
  • Sacks D , Noben-TrauthN: The immunology of susceptibility and resistance to Leishmania major in mice.Nat. Rev. Immunol.2(11) , 845–858 (2002).
  • Alexander J , BrysonK: T helper (h)1/Th2 and Leishmania: paradox rather than paradigm.Immunol. Lett.99(1) , 17–23 (2005).
  • Mansueto P , VitaleG, Di Lorenzo G, Rini GB, Mansueto S, Cillari E: Immunopathology of leishmaniasis: an update. Int. J. Immunopathol. Pharmacol.20(3) , 435–445 (2007).
  • Melby PC , Andrade-NarvaezFJ, DarnellBJ, Valencia-PachecoG, TryonVV, Palomo-CetinaA: Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis.Infect. Immun.62(3) , 837–842 (1994).
  • Pirmez C , YamamuraM, UyemuraK, Paes-OliveiraM, Conceição-SilvaF, ModlinRL: Cytokine patterns in the pathogenesis of human leishmaniasis.J. Clin. Invest.91(4) , 1390–1395 (1993).
  • Machado-Coelho GL , CaiaffaWT, GenaroO, MagalhãesPA, MayrinkW: Risk factors for mucosal manifestation of American cutaneous leishmaniasis.Trans. R. Soc. Trop. Med. Hyg.99(1) , 55–61 (2005).
  • Pasqua F , EnaJ, SanchezR et al.: Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterranean region.Eur. J. Clin. Microbiol. Infect. Dis.24(6) , 411–418 (2005).
  • Gillespie RD , MbowML, TitusRG: The immunomodulatory factors of bloodfeeding arthropod saliva.Parasite Immunol.98 , 153–159 (2000).
  • Reithinger R , DujardinJC, LouzirH, PirmezC, AlexanderB, BrookerS: Cutaneous leishmaniasis.Lancet Infect. Dis.7(9) , 581–596 (2007).
  • Lukes J , MauricioIL, SchönianG et al.: Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy.Proc. Natl Acad. Sci. USA104(22) , 9375–9380 (2007).
  • Buxbaum LU , DeniseH, CoombsGH, AlexanderJ, MottramJC, ScottP: Cysteine protease B of Leishmania mexicana inhibits host Th1 responses and protective immunity.J. Immunol.171 , 3711–3717 (2003).
  • Kelly BL , StetsonDB, LocksleyRM: Leishmania major LACK antigen is required for efficient vertebrate parasitization.J. Exp. Med.198 , 1689–1698 (2003).
  • Cupolillo E , BrahimLR, ToaldoCB et al.: Genetic polymorphism and molecular epidemiology of Leishmania (Viannia) braziliensis from different hosts and geographic areas in Brazil.J. Clin. Microbiol.41(7) , 3126–3132 (2003).
  • Schriefer A , SchrieferAL, Góes-NetoA et al.: Multiclonal Leishmania braziliensis population structure and its clinical implication in a region of endemicity for American tegumentary leishmaniasis.Infect. Immun.72(1) , 508–514 (2004).
  • Zerpa O , UlrichM, BlancoB et al.: Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses.Br. J. Dermatol.156(6) , 1328–1335 (2007).
  • Marovich MA , LiraR, ShepardM et al.: Leishmaniasis recidivans recurrence after 43 years: a clinical and immunologic report after successful treatment.Clin. Infect. Dis.33(7) , 1076–1079 (2001).
  • Ganguly S , DasNK, PanjaM et al.: Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis.J. Infect. Dis.197(12) , 1762–1771 (2008).
  • Zijlstra EE , MusaAM, KhalilEA, el-HassanIM, el-HassanAM: Post-kala-azar dermal leishmaniasis.Lancet Infect. Dis.3(2) , 87–98 (2003).
  • Marsden PD : Mucosal leishmaniasis (‘espundia‘).Trans. R. Soc. Trop. Med. Hyg.80 , 859–876 (1986).
  • Collin S , DavidsonR, RitmeijerK et al.: Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan.Clin. Infect. Dis.38(5) , 612–619 (2004).
  • Alvar J , CanavateC, Gutierrez-SolarB et al.: Leishmania and human immunodeficiency virus coinfection: the first 10 years.Clin. Microbiol. Rev.10 , 298–319 (1997).
  • Wortmann G , HochbergL, HoungHH et al.: Rapid identification of Leishmania complexes by a real-time PCR assay.Am. J. Trop. Med. Hyg.73(6) , 999–1004 (2005).
  • Murray HW , BermanJD, DaviesCR, SaraviaNG: Advances in leishmaniasis.Lancet366 , 1561–1577 (2005).
  • David C , Dimier-DavidL, VargasF, TorrezM, DedetJP: Fifteen years of cutaneous and mucocutaneous leishmaniasis in Bolivia: a retrospective study.Trans. R. Soc. Trop. Med.73 , 339–345 (1993).
  • Olliaro PL , GuerinPJ, GerstlS, HaaskjoldAA, RottingenJA, SundarS: Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004.Lancet Infect. Dis.5(12) , 763–774 (2005).
  • Ameen M : Cutaneous leishmaniasis: therapeutic strategies and future directions.Expert Opin. Pharmacother.8(16) , 2689–2699 (2007).
  • Amato VS , TuonFF, BachaHA, NetoVA, NicodemoAC: Mucosal leishmaniasis.Current scenario and prospects for treatment.Acta Trop.105(1) , 1–9 (2008).
  • Blum J , DesjeuxP, SchwartzE, BeckB, HatzC: Treatment of cutaneous leishmaniasis among travellers.J. Antimicrob. Chemother.53(2) , 158–166 (2004).
  • Bailey MS , GreenAD, EllisCJ et al.: Clinical guidelines for the management of cutaneous leishmaniasis in British military personnel.J. R. Army Med. Corps.151(2) , 73–80 (2005).
  • Modabber F : Experiences with vaccines against cutaneous leishmaniasis: of mice and men.Parasitology98(Suppl.) , S49–S60 (1989).
  • Requena JM , IborraS, CarrionJ, AlonsoC, SotoM: Recent advances in vaccines for leishmaniasis.Expert Opin. Biol. Ther.4 , 1505–1517 (2004).
  • Ivens AC , PeacockCS, WortheyEA et al.: The genome of the kinetoplastid parasite Leishmania major.Science309 , 436–442 (2005).
  • Stober CB , LangeUG, RobertsMT et al.: From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection.Vaccine24(14) , 2602–2616 (2006).
  • Convit J , UlrichM, ZerpaO et al.: Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990–1999.Trans. R. Soc. Trop. Med. Hyg.97(4) , 469–472 (2003).
  • Convit J , UlrichM, PolegreMA et al.: Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and Bacillus Calmette–Guerrin – preliminary report.Mem. Inst. Oswaldo Cruz91(1) , 57–62 (2004).
  • Musa AM , KhalilEA, MahgoubFA et al.: Leishmaniasis Research Group/Sudan. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment.Trans. R. Soc. Trop. Med. Hyg.102(1) , 58–63 (2008).
  • Jones TC , JohnsonWD, BarretoAC et al.: Epidemiology of American leishmaniasis due to Leishmania braziliensis braziliensis.J. Infect. Dis.156 , 73–83 (1987).
  • Castellucci L , ChengLH, AraújoC et al.: Familial aggregation of mucosal leishmaniasis in northeast Brazil.Am. J. Trop. Med. Hyg.73(1) , 69–73 (2005).
  • Walton BC , ValverdeL: Racial differences in espundia.Ann. Trop. Med. Parasitol.73(1) , 23–29 (1979).
  • Al-Gindan Y , Abdul-AzizO, KubbaR: Cutaneous leishmaniasis in Al-Hassa, Saudi Arabia.Int. J. Dermatol.23(3) , 194–197 (1984).
  • Shaw MA , DaviesCR, Llanos-CuentasEA, CollinsA: Human genetic susceptibility and infection with Leishmania peruviana.Am. J. Hum. Genet.57(5) , 1159–1168 (1995).
  • Alcaïs A , AbelL, DavidC, TorrezME, FlandreP, DedetJP: Evidence for a major gene controlling susceptibility to tegumentary leishmaniasis in a recently exposed Bolivian population.Am. J. Hum. Genet.61(4) , 968–979 (1997).
  • Samaranayake TN , DissanayakeVH, FernandoSD: Clinical manifestations of cutaneous leishmaniasis in Sri Lanka – possible evidence for genetic susceptibility among the Sinhalese.Ann. Trop. Med. Parasitol.102(5) , 383–390 (2008).
  • Mebrahtu YB , van Eys G, Guizani I et al.: Human cutaneous leishmaniasis caused by Leishmania donovani s.l. in Kenya. Trans. R. Soc. Trop. Med. Hyg.87(5) , 598–601 (1993).
  • Pratlong F , BastienP, PerelloR, LamiP, DedetJP: Human cutaneous leishmaniasis caused by Leishmania donovani sensu stricto in Yemen.Trans. R. Soc. Trop. Med. Hyg.89 , 398–399 (1995).
  • Antoniou M , HaralambousC, MazerisA et al.: Leishmania donovani leishmaniasis in Cyprus.Lancet Infect. Dis.8(1) , 6–7 (2008).
  • Cabello PH , LimaAM, AzevedoES, KrigerH: Familial aggregation of Leishmania chagasi infection in northeastern Brazil.Am. J. Trop. Med. Hyg.52 , 364–365 (1995).
  • Peacock CS , CollinsA, ShawMA et al.: Genetic epidemiology of visceral leishmaniasis in northeastern Brazil.Genet. Epidemiol.20 , 383–396 (2001).
  • Zijlstra EE , El Hassan AM, Ismael A, Ghalib HW: Endemic kala-azar in Eastern Sudan, a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am. J. Trop. Med. Hyg.51 , 826–836 (1994).
  • Ibrahim ME , LambsonB, YousifAO et al.: Kala-azar in a high transmission focus: An ethnic and geographic dimension.Am. J. Trop. Med. Hyg.61 , 941–944 (1999).
  • Handman E , ElsoC, FooteS: Genes and susceptibility to leishmaniasis.Adv. Parasitol.59 , 1–75 (2005).
  • Blackwell J , FreemanJ, BradleyD: Influence of H-2 complex on acquired resistance to Leishmania donovani infection in mice.Nature283(5742) , 72–74 (1980).
  • Vidal S , TremblayML, GovoniG et al.: The Ity/Lsh/Bcg locus: natural resistance to infection with intracellular parasites is abrogated by disruption of the Nramp1 gene.J. Exp. Med.182(3) , 655–666 (1995).
  • Roberts LJ , BaldwinTM, CurtisJM, HandmanE, FooteSJ: Resistance to Leishmania major is linked to the H2 region on chromosome 17 and to chromosome 9.J. Exp. Med.185(9) , 1705–1710 (1997).
  • Lipoldová M , SvobodováM, KrulováM et al.: Susceptibility to Leishmania major infection in mice: multiple loci and heterogeneity of immunopathological phenotypes.Genes Immun.1(3) , 200–206 (2000).
  • Heinzel FP , SadickMD, HoladayBJ, CoffmanRL, LocksleyRM: Reciprocal expression of interferon-γ or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets.J. Exp. Med.169(1) , 59–72 (1989).
  • Foote SJ , HandmanE: Genetics of murine leishmaniasis.Brief. Funct. Genomic. Proteomic.4(3) , 270–276 (2005).
  • Lipoldová M , DemantP: Genetic susceptibility to infectious disease: lessons from mouse models of leishmaniasis.Nat. Rev. Genet.7(4) , 294–305 (2006).
  • Lara ML , LayrisseZ, ScorzaJV et al.: Immunogenetics of human American cutaneous leishmaniasis. Study of HLA haplotypes in 24 families from Venezuela.Hum. Immunol.30(2) , 129–135 (1991).
  • Petzl-Erler ML , BelichMP, Queiroz-TellesF: Association of mucosal leishmaniasis with HLA.Hum. Immunol.32(4) , 254–260 (1991).
  • Barbier D , DemenaisF, LefaitJF et al.: Susceptibility to human cutaneous leishmaniasis and HLA, Gm, Km markers.Tissue Antigens30(2) , 63–67 (1987).
  • Olivo-Diaz A , DebazH, AlaezC et al.: Role of HLA class II alleles in susceptibility to and protection from localized cutaneous leishmaniasis.Hum. Immunol.65(3) , 255–261 (2004).
  • Singh N , SundarS, WilliamsF et al.: Molecular typing of HLA class I and class II antigens in Indian kala-azar patients.Trop. Med. Int. Health2(5) , 468–471 (1997).
  • Peacock CS , SanjeeviCB, ShawMA et al.: Genetic analysis of multicase families of visceral leishmaniasis in northeastern Brazil: no major role for class II or class III regions of HLA.Genes Immun.3(6) , 350–358 (2002).
  • Castes M , TrujilloD, RojasME et al.: Serum levels of tumour necrosis factor in patients with American cutaneous lesihmaniasis.Biol. Res.26 , 233–238 (1993).
  • Barral-Netto M , BadaróR, BarralA et al.: Tumor necrosis factor (cachectin) in human visceral leishmaniasis.J. Infect. Dis.163(4) , 853–857 (1991).
  • Cabrera M , ShawMA, ShraplesC et al.: Polymorphism in tumour necrosis factor genes associated with mucocutaneous leishmaniasis.J. Exp. Med.182(5) , 1259–1264 (1995).
  • Karplus TM , JeronimoSM, ChangH et al.: Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection.Infect. Immun.70(12) , 6919–6925 (2002).
  • Meddeb-Garnaoui A , GritliS, GarboujS et al.: Association analysis of HLA-class II and class III gene polymorphisms in the susceptibility to mediterranean visceral leishmaniasis.Hum. Immunol.62(5) , 509–517 (2001).
  • Kamali-Sarvestani E , RasouliM, MortazaviH, Gharesi-FardB: Cytokine gene polymorphisms and susceptibility to cutaneous leishmaniasis in Iranian patients.Cytokine35(3–4) , 159–165 (2006).
  • Chatelain R , VarkilaK, CoffmanRL: IL-4 induces a Th2 response in Leishmania major-infected mice.J. Immunol.148(4) , 1182–1187 (1992).
  • Kopf M , BrombacherF, KöhlerG et al.: IL-4-deficient Balb/c mice resist infection with Leishmania major.J. Exp. Med.184(3) , 1127–1136 (1996).
  • Heinzel FP , RerkoRM: Cure of progressive murine leishmaniasis: interleukin 4 dominance is abolished by transient CD4(+) T cell depletion and T helper cell Type 1-selective cytokine therapy.J. Exp. Med.189(12) , 1895–1906 (1999).
  • Mohamed HS , IbrahimME, MillerEN et al.: Genetic susceptibility to visceral leishmaniasis in The Sudan: linkage and association with IL4 and IFNGR1.Genes Immun.4 , 351–355 (2003).
  • Salhi A , RodriguesV Jr, Santoro F et al.: Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J. Immunol.180(9) , 6139–6148 (2008).
  • Bacellar O , LessaH, SchrieferA et al.: Up-regulation of Th1-type responses in mucosal leishmaniasis patients.Infect. Immun.70 , 6734–6740 (2002).
  • Hatzigeorgiou DE , HeS, SobelJ, GrabsteinKH, HafnerA, HoJL: IL-6 down-modulates the cytokine-enhanced antileishmanial activity in human macrophages.J. Immunol.151 , 3682–3692 (1993).
  • Castellucci L , MenezesE, OliveiraJ et al.: IL6 -174 G/C promoter polymorphism influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil.J. Infect. Dis.194(4) , 519–527 (2006).
  • Bucheton B , AbelL, El-SafiS et al.: A major susceptibility locus on chromosome 22q12 plays a critical role in the control of kala-azar.Am. J. Hum. Genet.73 , 1052–1060 (2003).
  • Barral-Netto M , BarralA, SantosSB et al.: Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis.J. Immunol.147(1) , 281–284 (1991).
  • Bucheton B , ArgiroL, ChevillardC et al.: Identification of a novel G245R polymorphism in the IL-2 receptor-β membrane proximal domain associated with human visceral leishmaniasis.Genes Immun.8(1) , 79–83 (2007).
  • Miller EN , FadlM, MohamedHS et al.: Y chromosome lineage- and village-specific genes on chromosomes 1p22 and 6q27 control visceral leishmaniasis in Sudan.PLoS Genet.3(5) , E71 (2007).
  • Jamieson SE , MillerEN, PeacockCS et al.: Genome-wide scan for visceral leishmaniasis susceptibility genes in Brazil.Genes Immun.8(1) , 84–90 (2007).
  • Jamieson SE , MillerEN, BlackGF et al.: Evidence for a cluster of genes on chromosome 17q11-q21 controlling susceptibility to tuberculosis and leprosy in Brazilians.Genes Immun.5(1) , 46–57 (2004).
  • Jeronimo SM , HolstAK, JamiesonSE et al.: Genes at human chromosome 5q31.1 regulate delayed-type hypersensitivity responses associated with Leishmania chagasi infection.Genes Immun.8(7) , 539–551 (2007).
  • Jeronimo SM , DuggalP, EttingerNA et al.: Genetic predisposition to self-curing infection with the protozoan Leishmania chagasi: a genomewide scan.J. Infect. Dis.196 , 1261–1269 (2007).
  • Bellamy R , RuwendeC, CorrahT, McAdamKPWJ, WhittleHC, HillAVS: Variation in the NRAMP1gene is associated with susceptibility to tuberculosis in West Africans.N. Engl. J. Med.338 , 640–644 (1998).
  • Bucheton B , AbelL, KheirMM et al.: Genetic control of visceral leishmaniasis in a Sudanese population: candidate gene testing indicates a linkage to the NRAMP1 region.Genes Immun.4 , 104–109 (2003).
  • Mohamed HS , IbrahimME, MillerEN et al.: SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in the Sudan.Eur. J. Hum. Genet.12 , 66–74 (2004).
  • Blackwell JM : SLC11A1 (formerly NRAMP1) and disease resistance.Cell. Microbiol.3 , 773–784 (2001).
  • Alonso DP , FerreiraAF, RibollaPE et al.: Genotypes of the mannan-binding lectin gene and susceptibility to visceral leishmaniasis and clinical complications.J. Infect. Dis.195 , 1212–1217 (2007).
  • Salih MA , IbrahimME, BlackwellJM et al.: IFNGand IFNGR1gene polymorphisms and susceptibility to post-kala-azar dermal leishmaniasis in Sudan.Genes Immun.8(1) , 75–78 (2007).
  • Casanova JL , AbelL: Genetic dissection of immunity to mycobacteria: The Human Model.Annu. Rev. Immunol.20 , 581–620 (2002).
  • Kane MM , MosserDM: The role of IL-10 in promoting disease progression in lesihmaniasis.J. Immunol.166 , 1141–1147 (2001).
  • Bourreau E , PrevotG, GardonJ, PradinaudR, LaunoisP: High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment.J. Infect. Dis.184 , 1628–1630 (2001).
  • Nylén S , SacksD: Interleukin-10 and the pathogenesis of human visceral leishmaniasis.Trends Immunol.28(9) , 378–384 (2007).
  • Saha S , MondalS, RavindranR et al.: IL-10- and TGF-β-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.J. Immunol.179(8) , 5592–5603 (2007).
  • Melby PC , Andrade-NarvaezF, DarnellBJ, Valencia-PachecoG: in situ expression of interleukin-10 and interleukin-12 in active human cutaneous leishmaniasis.FEMS Immunol. Med. Microbiol.15 , 101–107 (1996).
  • Louzir H , MelbyPC, Ben Salah A et al.: Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. J. Infect. Dis.177 , 1687–1695 (1998).
  • Faria DR , GollobKJ, BarbosaJ Jr et al.: Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect. Immun.73(12) , 7853–7859 (2005).
  • Peacock CS , SeegerK, HarrisD et al.: Comparative genomic analysis of three Leishmania species that cause diverse human disease.Nat. Genet.39(7) , 839–847 (2007).
  • Smith DF , PeacockCS, CruzAK: Comparative genomics: from genotype to disease phenotype in the leishmaniases.Int. J. Parasitol.37(11) , 1173–1186 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.